Reports

To assist health care providers, policy-makers, and consumers in making well-informed decisions about second- and third-line therapy for patients with inadequately controlled diabetes, our completed research and resulting recommendations are available in a series of Optimal Therapy Reports  that provide:

• evidence-based recommendations for optimal prescribing and use
• a clear picture of current practice and current utilization in Canada
• an outline of gaps between current prescribing and use.

Summary Reports

• Summary Report - Second- and Third-Line Therapy for Patients with Type 2 Diabetes
• Project in Brief - a one-page summary of CADTH work on second- and third-line therapies for diabetes.

Final Reports on Second-Line Therapy

• Optimal Therapy Recommendations for the Prescribing and Use of Second-Line Therapy for Patients with Diabetes Inadequately Controlled on Metformin. Optimal Therapy Report – COMPUS 2010;4(5).
• Second-Line Therapy for Patients With Diabetes Inadequately Controlled on Metformin: A Systematic Review and Cost-Effectiveness Analysis. Optimal Therapy Report – COMPUS 2010;4(2).
• Addendum - Second-line therapy for patients with diabetes when inadequately controlled on metformin — PROJECT PROTOCOL. Optimal Therapy Report - COMPUS 2009;4(1).
• Second-line therapy for patients with diabetes when inadequately controlled on metformin — PROJECT PROTOCOL. Optimal Therapy Report - COMPUS 2009;4(1).

Final Reports on Third-Line Therapy

• CADTH Therapeutic Review Economic Evaluation: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and Sulfonylurea Combination Therapy (34 pages).
• CADTH Therapeutic Review Clinical Review: Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea (205 pages).
• CADTH Therapeutic Review Panel Recommendations Report. Third-Line Therapy for Patients with Type 2 Diabetes Inadequately Controlled with Metformin and a Sulfonylurea (21 pages).

Final Reports on Current Practice and Use

• Current Practice Analysis of Health Care Providers and Patients: Second-line Therapy for Patients With Type 2 Diabetes Inadequately Controlled on Metformin. Optimal Therapy Report - COMPUS 2010;4(4).
• Current Utilization of Second- and Third-Line Therapies in Patients with Type 2 Diabetes. Optimal Therapy Report - COMPUS 2010;4(3).